Full OptIMMize-1 results show high skin clearance rates with risankizumab in children and teens with psoriasis, sustained through 52 weeks.
News|Articles|April 11, 2026
FDA tracker: Novel approvals in pediatrics during 2026
Author(s)Celeste Krewson, Assistant Editor
Fact checked by: Kelly King
A review of 6 novel drugs approved by the FDA, with links to coverage from Contemporary Pediatrics and other MJH Life Sciences brands.
Advertisement
Advertisement
Multiple strides in pediatric care have been reported so far in 2026, marking a transformative year for the treatment of rare pediatric disorders and chronic dermatologic conditions. From the first targeted therapy for neurologic complications in Hunter syndrome and novel interventions for ultrarare diseases such as Menkes disease and arginase 1 deficiency, to historic firsts in oral and topical treatments for plaque psoriasis and atopic dermatitis in children and adolescents, clinical innovation is rapidly expanding the therapeutic tool kit available to pediatricians.
Related to this article
Cenobamate sNDAs target PGTC seizures in patients ≥12 years and pediatric focal seizures; phase 3 PGTC data showed a 71.9% median reduction.
FDA approved Lupin's generic of Firdapse for LEMS in patients 6 years and older, but a patent settlement delays US marketing until at least 2035.
Topical botanical Cinainu earned FDA Breakthrough Therapy status for AA in patients aged 2+, supported by phase 2/3 RAAINBOW data in children.
In a matched cohort of children aged 6 and younger with EoE, dupilumab was linked to less incident asthma than swallowed budesonide (10.5% vs 16.2%).
Emily Becker, MD, discusses the role of AhR agonists, skin barrier function, and steroid-free treatment options for pediatric atopic dermatitis.
Post hoc data show cariprazine improved both manic and depressive symptoms through 52 weeks in youth aged 10 to 17 years with bipolar I disorder.
A meta-analysis of 52 studies links NO2, SO2, and particulate matter to more pediatric atopic dermatitis visits and higher prevalence.
Advertisement
Advertisement